Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
GTY
2651
Getty Realty Corp
GTY
$1.75B
| $2.82M | ﹤0.01% |
102,988
+10,594
| +11% | +$293K |
2013 Q2
50 quarters
|
|
2652
Digi International
DGII
$2.87B
| $2.81M | ﹤0.01% |
65,011
+5,074
| +8% | +$203K |
2022 Q3
13 quarters
|
|
2653
Parsons
PSN
$4.36B
| $2.81M | ﹤0.01% |
45,463
-10,635
| -19% | -$832K |
2019 Q2
26 quarters
|
|
|
TWO
2654
DELISTED
Two Harbors Investment
TWO
| $2.81M | ﹤0.01% |
267,420
-71,224
| -21% | -$712K |
2013 Q2
50 quarters
|
|
2655
Castle Biosciences
CSTL
$1.09B
| $2.81M | ﹤0.01% |
72,149
-919
| -1% | -$29.6K |
2022 Q1
15 quarters
|
|
2656
Astronics
ATRO
$2.93B
| $2.81M | ﹤0.01% |
62,065
+10,364
| +20% | +$435K |
2013 Q2
50 quarters
|
|
2657
Old Second Bancorp
OSBC
$1.27B
| $2.79M | ﹤0.01% |
143,188
+26,609
| +23% | +$497K |
2016 Q2
38 quarters
|
|
2658
Cullinan Oncology
CGEM
$998M
| $2.79M | ﹤0.01% |
269,655
+18,545
| +7% | +$167K |
2022 Q1
15 quarters
|
|
|
SOLS
2659
CALL
Solstice Advanced Materials
SOLS
$9.17B
| $2.79M | ﹤0.01% |
+57,450
| New | +$2.7M |
2025 Q4
0 quarters
|
|
2660
Rogers Corp
ROG
$2.86B
| $2.79M | ﹤0.01% |
30,477
+3,972
| +15% | +$341K |
2013 Q2
50 quarters
|
|
2661
Navitas Semiconductor
NVTS
$3.26B
| $2.78M | ﹤0.01% |
388,850
+200,202
| +106% | +$1.93M |
2023 Q1
11 quarters
|
|
2662
Fortuna Silver Mines
FSM
$3.33B
| $2.77M | ﹤0.01% |
282,605
+7,745
| +3% | +$69.7K |
2024 Q3
5 quarters
|
|
2663
Chemours
CC
$2.06B
| $2.77M | ﹤0.01% |
234,956
-701,328
| -75% | -$9M |
2015 Q3
41 quarters
|
|
2664
nLIGHT
LASR
$2.34B
| $2.77M | ﹤0.01% |
73,759
+6,015
| +9% | +$201K |
2018 Q2
30 quarters
|
|
|
HTB
2665
HomeTrust Bancshares
HTB
$770M
| $2.77M | ﹤0.01% |
64,430
-645
| -1% | -$26.6K |
2013 Q2
50 quarters
|
|
2666
Amalgamated Financial
AMAL
$1.44B
| $2.76M | ﹤0.01% |
86,316
+22,444
| +35% | +$653K |
2022 Q1
15 quarters
|
|
2667
Northrim BanCorp
NRIM
$551M
| $2.76M | ﹤0.01% |
103,895
+5,481
| +6% | +$130K |
2016 Q3
37 quarters
|
|
2668
Silgan Holdings
SLGN
$3.69B
| $2.76M | ﹤0.01% |
68,468
-31,883
| -32% | -$1.29M |
2013 Q2
50 quarters
|
|
2669
Harrow
HROW
$1.14B
| $2.76M | ﹤0.01% |
56,380
+2,009
| +4% | +$84.3K |
2021 Q2
18 quarters
|
|
2670
PUT
Remitly
RELY
$4.61B
| $2.76M | ﹤0.01% |
200,000
| – | – |
2025 Q3
1 quarter
|
|
2671
Arlo Technologies
ARLO
$1.38B
| $2.76M | ﹤0.01% |
197,262
+23,897
| +14% | +$376K |
2018 Q3
29 quarters
|
|
2672
Sunstone Hotel Investors
SHO
$2.12B
| $2.76M | ﹤0.01% |
308,643
+2,011
| +0.7% | +$18.4K |
2013 Q2
50 quarters
|
|
2673
PUT
Insulet
PODD
$9.13B
| $2.76M | ﹤0.01% |
9,700
| – | – |
2025 Q2
2 quarters
|
|
2674
Vishay Intertechnology
VSH
$5.86B
| $2.75M | ﹤0.01% |
190,109
-11,363
| -6% | -$172K |
2013 Q2
50 quarters
|
|
2675
Ceco Environmental
CECO
$4.31B
| $2.75M | ﹤0.01% |
45,985
-4,185
| -8% | -$224K |
2016 Q2
38 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.